Giacomo Drius

Dr. Giacomo Drius

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Molecules
Verified
Journal Article
Open access
PDF file
GMGabriele Micheletti
Gabriele Micheletti
Carla BogaCarla Boga
Carla Boga
GDGiacomo Drius
Giacomo Drius
silvia bordonisilvia bordoni
silvia bordoni
NCNatalia Calonghi
Natalia Calonghi
This review covers the last 25 years of the literature on analogs of suberoylanilide hydroxamic acid (SAHA, known also as vorinostat) acting as an HDAC inhibitor. In particular, the topic has been focused on the synthesis and biological activity of compounds where the phenyl group (the surface recognition moiety, CAP) of SAHA has been replaced by an azaheterocycle through a direct bond with amide nitrogen atom, and the methylene chain in the linker region is of variable length. Most of the compounds displayed good to excellent inhibitory activity against HDACs and in many cases showed antiproliferative activity against human cancer cell lines.

12 May 2023 in Molecules
Verified
Journal Article
Open access
PDF file
GDGiacomo Drius
Giacomo Drius
silvia bordonisilvia bordoni
silvia bordoni
Carla BogaCarla Boga
Carla Boga
MMMagda Monari
Magda Monari
Jessica FioriJessica Fiori
Jessica Fiori
GMGabriele Micheletti
Gabriele Micheletti
Metallodrugs represent a combination of multifunctionalities that are present concomitantly and can act differently on diverse biotargets. Their efficacy is often related to the lipophilic features exhibited both by long carbo-chains and the phosphine ligands. Three Ru(II) complexes containing hydroxy stearic acids (HSAs) were successfully synthesized in order to evaluate possible synergistic effects between the known antitumor activity of HSA bio-ligands and the metal center. HSAs were reacted with [Ru(H)2CO(PPh3)3] selectively affording O,O-carboxy bidentate complexes. The organometallic species were fully characterized spectroscopically using ESI-MS, IR, UV-Vis, and NMR techniques. The structure of the compound Ru-12-HSA was also determined using single crystal X-ray diffraction. The biological potency of ruthenium complexes (Ru-7-HSA, Ru-9-HSA, and Ru-12-HSA) was studied on human primary cell lines (HT29, HeLa, and IGROV1). To obtain detailed information about anticancer properties, tests for cytotoxicity, cell proliferation, and DNA damage were performed. The results demonstrate that the new ruthenium complexes, Ru-7-HSA and Ru-9-HSA, possess biological activity. Furthermore, we observed that the Ru-9-HSA complex shows increased antitumor activity on colon cancer cells, HT29.

22 November 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
GMGabriele Micheletti
Gabriele Micheletti
Carla BogaCarla Boga
Carla Boga
GDGiacomo Drius
Giacomo Drius
silvia bordonisilvia bordoni
silvia bordoni
NCNatalia Calonghi
Natalia Calonghi
This review covers the last 25 years literature on analogs of suberoylanilide hydroxamic acid (SAHA, known also as Vorinostat) acting as HDAC inhibitor. In particular, the topic has been focused on the synthesis and biological activity of compounds where the phenyl group (the surface recognition moiety, CAP) of SAHA has been replaced by an azaheterocycle through a direct bond with amide nitrogen atom, and the methylene chain in the linker region is of variable length. Most of the compounds reported displayed good to excellent inhibitory activity against HDACs and in many cases showed anti-proliferative activity against human cancer cell lines.

9 May 2023 in Molecules
Verified
Journal Article
Open access
PDF file
silvia bordonisilvia bordoni
silvia bordoni
RTRiccardo Tarroni
Riccardo Tarroni
MMMagda Monari
Magda Monari
SCStefano Cerini
Stefano Cerini
FBFabio Battaglia
Fabio Battaglia
GDGiacomo Drius
Giacomo Drius
The reaction of mer-(Ru(H)2(CO)(PPh3)3) (1) with one equivalent of thymine acetic acid (THAcH) unexpectedly produces the macrocyclic dimer k1(O), k2(N,O)-(Ru(CO)(PPh3)2THAc)2 (4) and, concomitantly, the doubly coordinated species k1(O), k2(O,O)-(Ru(CO)(PPh3)2THAc) (5). The reaction promptly forms a complicated mixture of Ru-coordinated mononuclear species. With the aim of shedding some light in this context, two plausible reaction paths were proposed by attributing the isolated or spectroscopically intercepted intermediates on the basis of DFT-calculated energetic considerations. The cleavage of the sterically demanding equatorial phosphine in the mer-species releases enough energy to enable self-aggregation, producing the stable, symmetric 14-membered binuclear macrocycle of 4. The k1-acetate iminol (C=N-OH) unit of the mer-tautomer k1(O)-(Ru(CO)(PPh3)2(THAc)) (2) likely exhibits a stronger nucleophilic aptitude than the prevalent N(H)-C(O) amido species, thus accomplishing extra stabilization through concomitant k2(N,O)-thymine heteroleptic side-chelation. Furthermore, both the ESI-Ms and IR simulation spectra validated the related dimeric arrangement in solution, in agreement with the X-ray determination of the structure. The latter showed tautomerization to the iminol form. The 1H NMR spectra in chlorinated solvents of the kinetic mixture showed the simultaneous presence of 4 and the doubly coordinated 5, in rather similar amounts. THAcH added in excess preferentially reacts with 2 or trans-k2(O,O)-(RuH(CO)(PPh3)2THAc) (3) rather than attacking the starting Complex 1, promptly forming the species of 5. The proposed reaction paths were inferred by spectroscopically monitoring the intermediate species, for which the results were strongly dependent on the of conditions the reaction (stoichiometry, solvent polarity, time, and the concentration of the mixture). The selected mechanism proved to be more reliable, due to the final dimeric product stereochemistry.

9 February 2026 in Molecules
Verified
Journal Article
Open access
PDF file
silvia bordonisilvia bordoni
silvia bordoni
MMMagda Monari
Magda Monari
Carla BogaCarla Boga
Carla Boga
Federico MoroFederico Moro
Federico Moro
GDGiacomo Drius
Giacomo Drius
The use of metal-based species bearing existing pharmaceuticals as ligands—often resulting in enhanced bioactivity—represents an attractive strategy for the development of novel therapeutic formulations. In this context, five well-known non-steroidal anti-inflammatory drugs (NSAIDs) were employed to substitute both PPh3 and hydride ligands in [Ru(H)2(CO)(PPh3)3] (1), thereby selectively affording neutral κ2-(O,O)–chelate complexes in satisfactory yields via molecular hydrogen release. Among the obtained species, two complexes coordinating diclofenac (4) and aspirin (5) were further investigated by single-crystal X-ray diffraction (SCXRD). Preliminary biological studies were conducted on the ruthenium–salicylic acid species 2 and ibuprofen 6. The former showed promising antiproliferative activity against HeLa cancer cells, consistent with the well-established role of NSAID–ruthenium(II) complexes as a platform for the development of novel anticancer metallotherapeutics.

19 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
silvia bordonisilvia bordoni
silvia bordoni
MMMagda Monari
Magda Monari
Carla BogaCarla Boga
Carla Boga
Federico MoroFederico Moro
Federico Moro
GDGiacomo Drius
Giacomo Drius
The use of metal-based species bearing existing pharmaceuticals as ligands, often resulting in enhanced bioactivity, represents an attractive strategy for the development of novel therapeutic formulations. In the context, five well-known non-steroidal anti-inflammatory drugs (NSAIDs) were employed to substitute both PPh₃ and hydride ligands in [Ru(H)₂(CO)(PPh₃)₃] (1), selectively affording, via molecular hydrogen release, neutral κ²-(O,O)-chelate complexes in satisfactory yields. Among the obtained species, two complexes coordinating diclofenac (4) and aspirin (5) were further investigated by single-crystal X-ray diffraction (SCXRD). Preliminary biological studies on the ruthenium-salicylic acid species 2 showed promising antiproliferative activity against HeLa cancer cells, consistent with the fact that NSAID–ruthenium(II) complexes represent a well-established research area for the development of novel anticancer metallotherapeutics.